Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 15/20 | 0.52 |
| ▸ | DDB1 | Q16531 | 3/20 | 0.52 |
| ▸ | IKZF3 | Q9UKT9 | 7/20 | 0.51 |
| ▸ | BRD4 | O60885 | 3/20 | 0.51 |
| ▸ | IKZF1 | Q13422 | 2/20 | 0.51 |
| ▸ | TNF | P01375 | 2/20 | 0.51 |
| ▸ | IL1B | P01584 | 1/20 | 0.51 |
| ▸ | MAP1LC3B | Q9GZQ8 | 2/20 | 0.47 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.44 |
| ▸ | STAT3 | P40763 | 1/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18666833 | 0.89 | CRBN (0.66) | CRBNDDB1IKZF3BRD4IKZF1 | |
| SCHEMBL21304408 | 0.89 | CRBN (0.66) | CRBNDDB1IKZF3BRD4IKZF1 | |
| SCHEMBL17897664 | 0.85 | CRBN (0.52) | CRBNDDB1IKZF3BRD4IKZF1 | |
| SCHEMBL21602724 | 0.84 | CRBN (0.51) | CRBNDDB1IKZF3BRD4IKZF1 | |
| SCHEMBL25679573 | 0.84 | CRBN (0.61) | CRBNDDB1IKZF3BRD4IKZF1 | |
| SCHEMBL25467697 | 0.84 | CRBN (0.55) | CRBNDDB1IKZF3BRD4IKZF1 | |
| SCHEMBL25467709 | 0.84 | CRBN (0.55) | CRBNDDB1IKZF3BRD4IKZF1 | |
| SCHEMBL18878463 | 0.84 | CRBN (0.55) | CRBNDDB1IKZF3BRD4IKZF1 | |
| SCHEMBL425119 | 0.82 | CRBN (0.49) | CRBNDDB1IKZF3BRD4IKZF1 | |
| SCHEMBL26141973 | 0.82 | CRBN (0.58) | CRBNDDB1IKZF3BRD4IKZF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11744896-B2 | Compositions, use, and method for CDK2-PROTACs for cancer therapy and hearing loss | CREIGHTON UNIVERSITY (US) | 2023-09-05 | — | — | US | disclosed |
| US-20230235077-A1 | MATERIALS AND METHODS OF TREATING CANCER | THE GENERAL HOSPITAL CORPORATION (US) | 2023-07-27 | — | — | US | disclosed |
| US-20230158159-A1 | CHIMERIC DEGRADERS OF CYCLIN-DEPENDENT KINASE 9 AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158159-A1 | CHIMERIC DEGRADERS OF CYCLIN-DEPENDENT KINASE 9 AND USES THEREOF | CDK9, CDK19, CRBN | CRBN 3/4885DDB1 603/4885IKZF3 1406/4885 |
| US-20230235077-A1 | MATERIALS AND METHODS OF TREATING CANCER | MALT1, CD274, TP53 | CRBN 344/4885DDB1 26/4885IKZF3 688/4885 |
| US-11744896-B2 | Compositions, use, and method for CDK2-PROTACs for cancer therapy and hearing loss | CDK2, CDK20, CDK2AP2 | CRBN 126/4885DDB1 179/4885IKZF3 1775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.